EMA Authorised: Qdenga (Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated;Dengue virus, serotype 2, live, attenuated) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The European Medicines Agency authorised Qdenga, a live attenuated tetravalent dengue vaccine from Takeda, for protection against dengue disease in the European…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Qdenga (TAK-003)

Snippet

Status: Authorised. Therapeutic area: Dengue. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 19/12/2025